Every 8-K that Natera Inc (NTRA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow NTRA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NTRA filings page.
Natera, Inc. reported strong second-quarter 2026 results, with total revenues of $752.8 million, up 37.7% from $546.6 million a year earlier, and gross margin of 64.5%. The company processed about 1,043,900 tests, including 296,700 oncology tests, and narrowed its net loss to $67.0 million, or $0.47 per share, from $100.9 million, or $0.74 per share, in the prior-year quarter. Cash, cash equivalents and restricted cash were $1,091.5 million at June 30, 2026, with $80.3 million outstanding under a UBS line of credit.
For 2026, Natera anticipates total revenue of $2.85 billion to $2.91 billion, gross margin of 64% to 66%, selling, general and administrative costs of $1.125 billion to $1.225 billion, research and development costs of $800 million to $900 million, and positive cash flow. Operational highlights included record growth in clinical molecular residual disease oncology volumes, three major regulatory approvals for the Signatera assay, expanded Medicare coverage for Prospera, and an enhanced Panorama NIPT with validated performance in low fetal fraction samples.
Natera, Inc. reported that Monica Bertagnolli has resigned from its Board of Directors and all board committees, effective July 1, 2026. She is leaving due to her new position with the National Academy of Medicine. The company states her resignation is not related to any disagreement over operations, policies, or practices.
Natera, Inc. filed an amended report to add XBRL data to a prior disclosure without changing any of the original information. The company’s Board of Directors increased its size from eleven to twelve members and appointed Dr. Thomas Lynch as a new independent Class I director effective June 2, 2026.
Dr. Lynch’s term runs until the 2028 annual meeting of stockholders, and he will serve on the Board’s Human Capital Committee. He will receive cash and equity compensation in line with other non-employee directors, including a stock unit award vesting in three equal installments on June 26 of 2027, 2028, and 2029.
Natera, Inc. reported the results of its annual stockholder meeting, where investors approved an amendment to the Amended and Restated 2015 Equity Incentive Plan, increasing shares reserved for issuance by 3.2 million shares of common stock.
Stockholders elected three Class II directors and one Class I director, each receiving more votes "for" than "withheld." They also ratified Ernst & Young LLP as independent registered public accounting firm, approved the advisory vote on executive compensation, and supported holding that advisory vote every year.
As of the record date, 142,778,493 shares were outstanding and entitled to vote, and 130,691,097 shares were represented in person or by proxy, satisfying quorum requirements.
Natera, Inc. expanded its Board of Directors from eleven to twelve members and appointed Thomas Lynch as a new director, effective June 2, 2026. He will serve as a Class I director with a term running until the 2028 annual stockholder meeting and has been deemed independent under Nasdaq standards. Lynch will join the Board’s Human Capital Committee and receive cash and equity compensation in line with Natera’s existing non-employee director program. His initial equity award will vest in three equal installments on June 26 of 2027, 2028, and 2029. The company also plans to enter into an indemnification agreement with him and notes there are no family relationships or related-party transactions requiring disclosure.
Natera, Inc. reported strong first quarter 2026 growth while remaining unprofitable. Total revenues rose to $696.6 million, up 38.8% from $501.8 million a year earlier, driven by higher test volume and better pricing. The company processed about 1,013,600 tests, including approximately 258,900 oncology tests, with clinical oncology volume up 54.4% year over year. Gross profit reached $450.8 million, giving a gross margin of 64.7%, slightly higher than 63.1% last year.
Total operating expenses increased to $538.6 million, largely from higher research and development and selling, general and administrative spending, including clinical trials and new product support. Natera posted a net loss of $85.1 million, or ($0.60) per diluted share, compared with a net loss of $66.9 million, or ($0.50) per share, in 2025. Cash, cash equivalents and restricted cash were $1,087.9 million as of March 31, 2026, slightly above $1,076.1 million at year-end 2025, and the company generated positive cash inflow of about $11.8 million in the quarter.
On the back of this performance, Natera raised its full-year 2026 revenue outlook from $2.62–$2.70 billion to $2.74–$2.82 billion and now expects gross margin around 64%–66%. Management highlighted record overall test volumes, strong women’s health growth supported by the Fetal Focus offering, and another record quarter in oncology testing, including momentum for its Signatera minimal residual disease test.
Natera, Inc. expanded its Board of Directors from ten to eleven members and appointed Eric Rubin as a Class I director, effective March 26, 2026. His initial term runs until the 2028 annual meeting of stockholders, and the Board has deemed him an independent director under Nasdaq standards.
Dr. Rubin will serve on the Board’s Nominating, Corporate Governance and Compliance Committee and receive cash and equity pay consistent with other non-employee directors under Natera’s Amended Compensation Program for Non-Employee Directors. His initial equity award will vest in three equal installments on March 26, 2027, 2028 and 2029.
The company also entered into an Indemnification Agreement with Dr. Rubin, providing indemnification and advancement of expenses to the fullest extent permitted by law for claims related to his service. There are no family relationships or related-party transactions requiring disclosure in connection with his appointment.
Natera, Inc. reported strong growth for the fourth quarter and full year 2025. Total revenue reached $665.5 million in Q4 2025, up 39.8% from Q4 2024, and $2,306.1 million for 2025, a 35.9% increase over 2024, driven mainly by higher product revenues and better pricing.
The company processed about 3.53 million tests in 2025, with oncology test volumes rising 51.6% to roughly 800,800. Gross margin improved to 64.7% for 2025, up from 60.3% in 2024, as scale and cost efficiencies took hold.
Natera achieved positive cash inflow of approximately $107.6 million in 2025, while still posting a net loss of $208.2 million, or ($1.52) per diluted share. Management guides 2026 revenue to $2.62–$2.70 billion with gross margin of 63%–65% and expects positive net cash inflow.
Natera, Inc. furnished a current report stating that on January 11, 2026, it issued a press release with preliminary financial results for its fourth quarter and full fiscal year ended December 31, 2025. The press release is included as Exhibit 99.1, giving investors an early look at the company’s recent performance ahead of full audited results. The company specifies that this information, including Exhibit 99.1, is being furnished rather than filed, which means it is not subject to certain liability provisions under the securities laws or automatically incorporated into other SEC filings unless expressly referenced.
Natera, Inc. furnished a Form 8‑K announcing results for its third quarter ended September 30, 2025, and provided a related investor presentation. The press release and presentation are included as Exhibits 99.1 and 99.2. The company states the information is furnished, not "filed," under the Exchange Act and is not incorporated into other filings unless expressly stated.